The chief medical officer at Avidity Biosciences talked about how its exon skipping AOC therapies are designed to address the lack of functional dystrophin protein among patients with Duchenne muscular dystrophy to improve muscle function. [WATCH TIME: 4 minutes]
The director of epilepsy surgery at Allegheny Health Network provided insight on the early discussions between patients with drug resistant epilepsy and clinicians seeking to find beneficial treatment strategies. [WATCH TIME: 3 minutes]
The associate professor in the department of population and quantitative health sciences at Case Western Reserve University School of Medicine talked about striving to understand and address the disparities among Latinx patients with multiple sclerosis. [WATCH TIME: 2 minutes]
A group of esteemed panelists discussed the important values neurology department directors and educators should prioritize when teaching students of the future. [WATCH TIME: 6 minutes]
Neurology News Network for the week ending September 2, 2023. [WATCH TIME: 3 minutes]
A trio of former and current neurology department directors discussed ways in which residency and fellowship programs may change as technology and therapeutic capabilities continue to expand. [WATCH TIME: 8 minutes]
The associate professor of neurological sciences at the University of Vermont in Burlington discussed the persistent issue of delayed and misdiagnoses among patients with multiple sclerosis, highlighting the need to improve accurate diagnosis. [WATCH TIME: 3 minutes]
A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]
The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, talked about the promising potential of BTK inhibitors in treating both relapsing and progressive forms of multiple sclerosis. [WATCH TIME: 6 minutes]
Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.
The chief medical officer at Avidity Biosciences discussed the phase 1/2 EXPLORE44 trial, assessing an investigational treatment for Duchenne muscular dystrophy, and highlighted the potential of the treatment based on the recent FDA orphan drug and fast track designations. [WATCH TIME: 4 minutes]
The associate staff member in the department of neurology at Cleveland Clinic discussed the major take-home points and post-hoc findings from a positive study of deep brain stimulation in poststroke patients. [WATCH TIME: 3 minutes]
The group of experts provided perspectives on the shift in how residency programs are developed and laid out, as well as efforts to increase the number of young neurologists in the field.
The professor of neurology at Washington University School of Medicine discussed the growing sense of hope among patients with progressive multiple sclerosis as providers gain an understanding in treating this form of the disease. [WATCH TIME: 3 minutes]
Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.
The neurosurgeon at Allegheny Health Network discussed the current uses of GammaTile following tumor removal, and the research needed to unlock greater potential. [WATCH TIME: 3 minutes]
The director of pharmacy at Emory Healthcare and Winship Cancer Institute talked about the role of pharmacists in multiple sclerosis patient care and collaborating with providers as biosimilars become available. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending August 26, 2023. [WATCH TIME: 3 minutes]
The neuromuscular and movement disorders speech-language pathologist at Orlando Health discussed strategies in managing the phases of multiple sclerosis for patients and the need for collaborative referral practices. [WATCH TIME: 5 minutes]
The assistant professor at Queen’s University discussed results from a pilot trial that evaluated the impact of a dyadic physical activity intervention among both caregivers and patients with multiple sclerosis. [WATCH TIME: 3 minutes]
Experts share insights on the latest innovations in multiple sclerosis research, in highlights from a recent State of the Science SummitTM, presented by Neurology Live®.
The executive vice president of the National MS Society provided perspective on the challenges with remyelinating strategies for patients with MS, and the progress that’s been made thus far. [WATCH TIME: 4 minutes]
The assistant professor at Hunter College talked about the importance of prioritizing accurate localization, appropriate diagnostic tests, and patient communication for effective neurological diagnosis, prognosis, and treatment. [WATCH TIME: 3 minutes]
The director of the Buffalo Neuroimaging Analysis Center talked about a study that explored cognitive decline in patients with early multiple sclerosis, underlining the significance of addressing cognitive impairment in the early stages of the disease. [WATCH TIME: 3 minutes]
The associate staff member in the department of neurology at Cleveland Clinic provided background on a recently published phase 1 trial showing benefits of DBS for chonic poststroke motor rehabilitation. [WATCH TIME: 3 minutes]
The associate vice president of neuroscience, US Medical Affairs at Eli Lilly talked about the "Think Talk Treat Migraine" program and the 3 vital actions for providers take to improve migraine care for their patients. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending August 19, 2023. [WATCH TIME: 4 minutes]
The headache specialist at the Hartford Healthcare Headache Center discussed findings from a study that revealed altered retinal vasculature in individuals with migraine with aura, indicating potential retinal biomarkers for disease progression. [WATCH TIME: 4 minutes]
The executive vice president of the National MS Society discussed the challenges with treating progressive forms of MS, and the accumulating neurodegeneration seen over time. [WATCH TIME: 4 minutes]
The senior vice president of research at Vaxxinity discussed recently published trial findings on a novel vaccine that targets Alzheimer disease and triggers the production of antibodies against toxic amyloid-ß peptides. [WATCH TIME: 9 minutes]
